ROADMAP FOR MELANOMA SCREENING PROGRAM
The four-year Government funded Roadmap for a National Targeted Melanoma Screening Program commenced in March 2025. Led by MIA, a team of experts and stakeholders is gathering evidence and will develop recommendations for how a program could work. Read latest updates.
LATEST NEWS
MPA-MIA Melanoma Community Webinar Series 2023
Watch recordings of our 2023 webinar series. The webinars cover Clinical Trials, Mucosal Melanoma, and Fear of Recurrence.
A warm community spirit at the MIA Amie St Clair Winter Wonderland Ball!
Enjoy our pics from the MIA Amie St Clair Winter Wonderland Ball, which capture all the fun!
In loving memory of Gina Savage
Gina Savage was a bright light to all who knew and loved her. We have created this tribute page so everyone can share their messages and memories.
Major advance for neoadjuvant treatment of melanoma
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.
Prof Richard Scolyer gains strength from widespread support
Family, friends, colleagues and MIA provide support and strength to Prof Richard Scolyer as he undergoes treatment for a glioblastoma (brain cancer).
MIA researchers share learnings on global stage at ASCO23
Read more about how the MIA team continues to play a leading role in pushing melanoma research boundaries at ASCO23, the world's leading clinical oncology conference.
MIA’s MISSION
ZERO DEATHS FROM MELANOMA
MIA will achieve its mission through 3 pillars of action: Research, Clinical Care & Education.
MIA conducts its research under 4 themes: Prevention, Risk & Clinical Detection – Early Melanoma – Advanced Melanoma – Supportive Care & Survivorship.
1300
It is estimated 1300 Australians will die from melanoma this year
30 mins
1 Australian is diagnosed with melanoma every 30 minutes
90%
If caught early 90% of melanomas can be cured by surgery
Age 20-39
Melanoma is the most common cancer affecting Australians aged 20 to 39
